Muscle inflammation classified as 'other myositis' where the anatomical site has not been documented or specified by the treating clinician.
Verified May 8, 2026 · 4 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 6
- Region
- General
Documentation tips
What should appear in the chart to support M60.80.
Source · Editorial brief grounded in 4 cited references ↓
- Record the specific muscle or anatomical region by name in every encounter note — even a general region (e.g., 'right thigh musculature') unlocks a more specific code than M60.80.
- Specify the type of myositis (drug-induced, ossificans, inflammatory NOS) so the coder can determine whether M60.8x, M60.0x, or an autoimmune-related code applies.
- If imaging (MRI, ultrasound) was performed, document which muscle group shows signal change or inflammation — this ties the site to the diagnosis and supports medical necessity.
- Document any excluded conditions explicitly ruled out (e.g., 'not inclusion body myositis, not dermatomyositis') to justify staying within M60 rather than G72.41 or M33.-.
- For drug-induced myositis, add a Use Additional Code for the causative drug (T36–T50 range) to complete the coding picture.
Related CPT procedures
Procedure codes commonly billed with M60.80. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M60.80 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Using M60.80 when site is actually documented — if the note names any anatomical region, drop to the appropriate M60.81–M60.89 site-specific code instead.
- Failing to exclude inclusion body myositis [IBM]: IBM codes to G72.41, not M60.8x; assigning M60.80 for a patient with confirmed IBM is a misclassification.
- Coding M60.80 for autoimmune-related myopathies (lupus, RA, scleroderma) — those conditions have disease-specific myopathy codes and are Excludes2 from the M60–M63 range.
- Treating M60.80 as equivalent to dermatomyositis or polymyositis — both belong in M33.- and are excluded from M60 entirely.
- Omitting a secondary code for drug-induced cases — when a medication is the documented cause, the drug's adverse effect code from T36–T50 should accompany M60.80.
Clinical context
Source · Editorial summary grounded in 4 cited references ↓
M60.80 is the fallback code within the M60.8 (Other myositis) subcategory when the affected muscle site is genuinely unknown or not recorded in the clinical documentation. It sits beneath parent code M60.8 and above site-specific codes such as M60.811 (right shoulder) through M60.89 (multiple sites). Use it only when you cannot determine — from the note, imaging report, or physical exam findings — which anatomical region is involved.
The M60.8x subcategory covers forms of myositis that do not fit the infective (M60.0), interstitial (M60.1), or foreign body granuloma (M60.2) categories. Examples include drug-induced myositis, myositis ossificans, and other inflammatory muscle conditions not better classified elsewhere. Inclusion body myositis [IBM] is explicitly excluded from all of M60 — it codes to G72.41. Similarly, dermatopolymyositis, myopathy in autoimmune conditions (lupus, scleroderma, Sjögren's, RA), and muscular dystrophies all have their own code families and are excluded from M60–M63.
In an orthopedic or musculoskeletal practice, M60.80 should be rare. If the provider's note identifies even a general region — shoulder girdle, thigh, lower leg — a site-specific code from M60.81–M60.89 is required. Reserve M60.80 for genuinely undocumented site, not for convenience or speed.
Sibling codes
Other billable codes under M60.8 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 4 cited references ↓
01When is M60.80 the correct code versus a site-specific M60.8x code?
02Does inclusion body myositis [IBM] code to M60.80?
03Can M60.80 be used for drug-induced myositis when no site is documented?
04Is M60.80 appropriate for dermatomyositis or polymyositis?
05Does M60.80 require a 7th character?
06What CPT procedures commonly pair with M60.80 in an orthopedic or PT setting?
07Are myopathies associated with systemic diseases (lupus, RA, scleroderma) coded under M60.80?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective October 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M60-/M60.80
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M60.80
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57311&ver=28
Mira AI Scribe
Mira AI Scribe captures the affected muscle region, inflammation type, imaging findings (MRI signal change, ultrasound echogenicity), any causative drug, and explicit exclusion of conditions like IBM or dermatomyositis from the provider's note. That site and etiology detail drives the code away from the unspecified M60.80 fallback to a billable site-specific code — preventing medical necessity denials and audit flags tied to chronic use of unspecified diagnoses.
See how Mira captures M60.80 documentation